Search results for "immunology [Encephalitis]"

showing 10 items of 3685 documents

Between-group competition and human cooperation.

2008

A distinctive feature of human behaviour is the widespread occurrence of cooperation among unrelated individuals. Explaining the maintenance of costly within-group cooperation is a challenge because the incentive to free ride on the efforts of other group members is expected to lead to decay of cooperation. However, the costs of cooperation can be diminished or overcome when there is competition at a higher level of organizational hierarchy. Here we show that competition between groups resolves the paradigmatic ‘public goods’ social dilemma and increases within-group cooperation and overall productivity. Further, group competition intensifies the moral emotions of anger and guilt associated…

social dilemmaCompetitive Behaviorpublic goodsmedia_common.quotation_subjectDecision MakingcooperationAngergroup competitionGeneral Biochemistry Genetics and Molecular BiologyConflict PsychologicalMarket economyGame TheoryPolitical scienceHumansCooperative BehaviorGeneral Environmental Sciencemedia_commonGeneral Immunology and MicrobiologyGroup conflictGeneral MedicineSocial dilemmaPublic goodmoralityMoralityIncentiveNorm (social)General Agricultural and Biological SciencesGame theorySocial psychologyResearch ArticleProceedings. Biological sciences
researchProduct

The value of synthetic linear epitope analogues of La/SSB for the detection of autoantibodies to La/SSB; specificity, sensitivity and comparison of m…

1998

SUMMARY In a previous study it was shown that La/SSB contains four linear epitopes, p147–154, p291–302, p301–318 and p349–364. The aim of the present study was to investigate the value of the synthetic epitope analogues of the La/SSB autoantigen for the detection of antibodies to La/SSB, in comparison with recombinant La and fragments of this protein. A total of 122 sera with anti-La/SSB activity, from patients with primary Sjögren's syndrome (pSS) or systemic lupus erythematosus (SLE), were tested in various peptide-based assays. In addition, 62 sera from pSS or SLE patients with other autoantibody specificities and 95 sera from healthy individuals were used as controls. The autoantibody s…

systemic lupusantigenic peptidesMolecular Sequence DataImmunologyDot blotPeptideprimary sjogrens-syndromeBiologyAutoantigensSensitivity and SpecificityEpitopelaw.inventionsjogren's syndromeEpitopesAntigenlawmedicineantibodiesHumansImmunology and AllergyAmino Acid SequenceAutoantibodiesImmunoassaychemistry.chemical_classificationla/ssbcriteriaLinear epitopemedicine.diagnostic_testla ss-bAutoantibodyOriginal Articlessystemic lupus-erythematosusautoantigenRecombinant ProteinsSjogren's SyndromeclassificationRibonucleoproteinschemistryImmunoassayImmunologyRecombinant DNAdiagnostic valueb cell epitopesClinical and Experimental Immunology
researchProduct

Dexamethasone premedication suppresses vaccine-induced immune responses against cancer

2020

ABSTRACT Glucocorticosteroids (GCS) have an established role in oncology and are administered to cancer patients in routine clinical care and in drug development trials as co-medication. Given their strong immune-suppressive activity, GCS may interfere with immune-oncology drugs. We are developing a therapeutic cancer vaccine, which is based on a liposomal formulation of tumor-antigen encoding RNA (RNA-LPX) and induces a strong T-cell response both in mice as well as in humans. In this study, we investigated in vivo in mice and in human PBMCs the effect of the commonly used long-acting GCS Dexamethasone (Dexa) on the efficacy of this vaccine format, with a particular focus on antigen-specif…

t-cell primingPremedicationmedicine.medical_treatmentImmunologyPriming (immunology)dexamethasoneglucocorticosteroidsProinflammatory cytokineMice03 medical and health sciences0302 clinical medicineImmune systemAntigenCancer immunotherapyNeoplasmsAnimalsHumansImmunology and AllergyMedicineRC254-282Original ResearchMice Inbred BALB Ccancer immunotherapybusiness.industryrna vaccineImmunityNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC581-607Mice Inbred C57BLCytokineOncology030220 oncology & carcinogenesisImmunologyt-cell vaccineFemaleCancer vaccineImmunologic diseases. AllergybusinessT-cell vaccineResearch Article030215 immunologyOncoImmunology
researchProduct

Distinctive attributes for predicted secondary structures at terminal sequences of non-classically secreted proteins from proteobacteria

2008

Abstract C- and N-terminal sequences (64 amino acid residues each) of 89 non-classically secreted type I, type III and type IV proteins (Swiss-Prot/TrEMBL) from proteobacteria were transformed into predicted secondary structures. Multivariate analysis of variance (MANOVA) confirmed the significance of location (C- or N-termini) and secretion type as essential factors in respect of quantitative representations of structured (a-helices, b-strands) and unstructured (coils) elements. The profiles of secondary structures were transcripted using unequal property values for helices, strands and coils and corresponding numerical vectors (independent variables) were subjected to multiple discriminan…

terminal sequencesMultiple discriminant analysisGeneral Immunology and MicrobiologybiologyQH301-705.5General Neurosciencesecondary structureComputational biologyLinear discriminant analysisbiology.organism_classificationBioinformaticsdiscriminant analysisGeneral Biochemistry Genetics and Molecular BiologyCross-validationSecretory proteinDiscriminantprotein secretionSecretionProteobacteriaBiology (General)General Agricultural and Biological SciencesProtein secondary structureproteobacteriaOpen Life Sciences
researchProduct

Editorial: Thymic Epithelial Cells: New Insights Into the Essential Driving Force of T-Cell Differentiation.

2021

thymic stromal cellsT-LymphocytesImmunologyThymus GlandBiology03 medical and health sciences0302 clinical medicinethymusmedicineImmunology and AllergyAnimalsHumansImmunodeficiency030304 developmental biologycentral tolerance0303 health sciencesCell DifferentiationEpithelial CellsRC581-607medicine.diseaseCell biologyEditorialT cell differentiationthymic epithelial cellsCentral toleranceImmunologic diseases. Allergyimmunodeficiency030215 immunologyFrontiers in immunology
researchProduct

Single-cell analysis of population context advances RNAi screening at multiple levels

2012

Isogenic cells in culture show strong variability, which arises from dynamic adaptations to the microenvironment of individual cells. Here we study the influence of the cell population context, which determines a single cell's microenvironment, in image‐based RNAi screens. We developed a comprehensive computational approach that employs Bayesian and multivariate methods at the single‐cell level. We applied these methods to 45 RNA interference screens of various sizes, including 7 druggable genome and 2 genome‐wide screens, analysing 17 different mammalian virus infections and four related cell physiological processes. Analysing cell‐based screens at this depth reveals widespread RNAi‐induce…

toImage ProcessingDruggabilityGenomeImage analysis0302 clinical medicineComputer-AssistedSX00 SystemsX.ch2604 Applied MathematicsSingle-cell analysisRNA interferenceModels2400 General Immunology and MicrobiologyImage Processing Computer-AssistedViralRNA Small Interfering0303 health scienceseducation.field_of_studyApplied MathematicsSystems BiologyGenomics10124 Institute of Molecular Life SciencesCell biologycell variabilityComputational Theory and MathematicsCellular MicroenvironmentVirus DiseasesVirusesRNA ViralRNA InterferenceSingle-Cell AnalysisGeneral Agricultural and Biological SciencesInformation SystemsSystems biologyVirus infectionPopulationContext (language use)Genomics1100 General Agricultural and Biological SciencesBiologySmall InterferingModels BiologicalGeneral Biochemistry Genetics and Molecular BiologySX08 LipidX03 medical and health sciencesViral ProteinsCell-to-cell variability; Image analysis; Population context; RNAi; Virus infection1300 General Biochemistry Genetics and Molecular BiologyHumansComputer Simulationeducation030304 developmental biologyGeneral Immunology and MicrobiologyCell-to-cell variabilityReproducibility of ResultsBayes TheoremcellBiologicalPopulation contextRNAi570 Life sciences; biologyRNA030217 neurology & neurosurgeryHeLa CellsMolecular Systems Biology
researchProduct

Interferon α interferes with immunological tolerance.

2013

The ability of regulatory T cells (Tregs) to promote immunological tolerance represents an important obstacle in cancer immunotherapy. We have recently discovered that the clinically established immunotherapeutic agent interferon α (IFNα) inactivates the suppressive functions of human Tregs. Here, we outline the mechanisms whereby IFNα mediates this important function and discuss its therapeutic implications for cancer immunotherapy.

tolerancebusiness.industrymedicine.medical_treatmentImmunologyImmunotherapeutic agentCancerNK cellsmedicine.diseasePDEregulatory T cellsIfn alphaOncologyCancer immunotherapyInterferon αcAMPImmunologymedicineImmunology and AllergycancerIFN-alphabusinessAuthor's ViewFunction (biology)Oncoimmunology
researchProduct

Mast cells as protectors of health.

2019

Mast cells (MCs), which are well known for their effector functions in T(H)2-skewed allergic and also autoimmune inflammation, have become increasingly acknowledged for their role in protection of health. It is now clear that they are also key modulators of immune responses at interface organs, such as the skin or gut. MCs can prime tissues for adequate inflammatory responses and cooperate with dendritic cells in T-cell activation. They also regulate harmful immune responses in trauma and help to successfully orchestrate pregnancy. This review focuses on the beneficial effects of MCs on tissue homeostasis and elimination of toxins or venoms. MCs can enhance pathogen clearance in many bacter…

tumorImmunologyvenomTryptaseMast cell; innate immunity; infection; mast cell protease; tumor; pregnancy; venom; toxin; central nervous system traumaInfectionsCell DegranulationMast Cell ; Innate Immunity ; Infection ; Mast Cell Protease ; Tumor ; Pregnancy ; Venom ; Toxin ; Central Nervous System TraumaImmune systemCathelicidinsPregnancymedicineImmunology and AllergyAnimalsHomeostasisHumansEmbryo ImplantationMast CellsCNS traumatoxininnate immunityTissue homeostasismast cell proteaseToll-like receptorTumor microenvironmentInnate immune systembiologybusiness.industryDegranulationMast cellhumanitiesImmunity InnateToll-Like Receptor 2infectionddc:medicine.anatomical_structureImmunologybiology.proteinFemalepregnancybusinessmast cell
researchProduct

Real-world experience with obeticholic acid in patients with primary biliary cholangitis

2021

Background & aims Obeticholic acid (OCA) is the second-line treatment approved for patients with primary biliary cholangitis (PBC) and an inadequate response or intolerance to ursodeoxycholic acid. We aimed to evaluate the effectiveness and safety of OCA under real-world conditions. Methods Patients were recruited into the Italian PBC Registry, a multicentre, observational cohort study that monitors patients with PBC at national level. The primary endpoint was the biochemical response according to Poise criteria; the secondary endpoint was the biochemical response according to normal range criteria, defined as normal levels of bilirubin, alkaline phosphatase (ALP), and alanine aminotransfer…

upper limit of normalCirrhosisALTAMAAutoimmunityantinuclear antibodiesULNPBCGastroenterologyUDCASettore MED/12ULN upper limit of normalobeticholic acidaRR adjusted risk ratio.CRFs case record formAST aspartate transferaseClinical endpointGGT gamma-glutamyl transferaseQCprimary biliary cholangitisGastroenterologyUrsodeoxycholic acidANATCCCirrhosisCholestasiTIPSTreatment Completer CohortANA antinuclear antibodiemedicine.medical_specialtyRRUDCA ursodeoxycholic acidTIPS transjugular intrahepatic portosystemic shuntOCACirrhosiALP alkaline phosphataseautoimmune hepatitismedicine.diseasedigestive system diseasesDiscontinuationKeywords: AIH autoimmune hepatitiQC quality controlchemistrygamma-glutamyl transferaserandomised controlled trialelectronic data captureantimitochondrial antibodiesaspartate transferaseAutoimmune hepatitischemistry.chemical_compoundAIHCRFsImmunology and Allergyadjusted risk ratioANA antinuclear antibodiesRR risk ratioOverall cohortALT alanine transferaseAMA antimitochondrial antibodieCholestasisCRFs case record formsObeticholic acidOverlap PBC-AIHursodeoxycholic acidOCA obeticholic acidTolerabilityalkaline phosphataseRCTResearch Articlemedicine.drugcase record formsContext (language use)AMA antimitochondrial antibodiesInternal medicineEDC electronic data capturetransjugular intrahepatic portosystemic shuntInternal MedicinemedicineRCT randomised controlled trialaRR adjusted risk ratioOClcsh:RC799-869quality controlalanine transferaseASTaRRHepatologybusiness.industryAutoimmunity; Cholestasis; Cirrhosis; Overlap PBC-AIHAIH autoimmune hepatitisTCC Treatment Completer CohortPBC primary biliary cholangitiGGTrisk ratioOC Overall cohortALPlcsh:Diseases of the digestive system. GastroenterologyPBC primary biliary cholangitisbusinessEDC
researchProduct

Could PD-1/PDL1 immune checkpoints be linked to HLA signature?

2019

The outstanding clinical expansion of monoclonal antibodies (mAbs) to programmed cell death receptor-1 (PD-1) (nivolumab and pembrolizumab) and PD-1 ligand-1 (PDL-1) (atezolizumab, avelumab and durvalumab) has received an increasing level of interest regarding immunotherapy and multidrug combinations, for the treatment of a number of common human malignancies. Some patients treated with these agents receive remarkable benefits in term of quality of life, progression-free (PFS) and overall survival (OS). However, a significant percentage of these patients experience immune-related adverse events (irAEs), while others present with an ultra-rapid disease progression, defined as hyperprogressio…

vDrug-Related Side Effects and Adverse ReactionsProgrammed Cell Death 1 ReceptorImmunologyAntibodies Monoclon alHuman leukocyte antigenB7-H1 AntigenImmune systemHLA AntigensirAENeoplasmsHumansImmunology and AllergyMedicinePD-1/PDL-1-blockadebusiness.industryAntibodies MonoclonalBiomarkerProgrammed Cell Death 1 ReceptorSignature (logic)HaplotypesOncologyImmunologyoutcomeImmunotherapyHLA alleleDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersB7-H1 AntigenImmunotherapy
researchProduct